Top Biotechnology companies in Switzerland by Revenue

This ranking features the top 22 Biotechnology companies in Switzerland ranked by Revenue, totaling a Revenue of USD 141.54 B, for June 25, 2025.

#	Name	Market Capitalization Share Price Year-To-Date (YTD) return Price to Earnings Ratio (P/E) EBIT EBITDA Net Income Free Cash Flow Dividend Yield Free Cash Flow Yield Total Assets Total Liabilities Cash and Short-Term Investments	Stock Price	Change	Price (30 days)	52W low/high	Sector

Items per page

Frequently Asked Questions

Which Biotechnology company in Switzerland has the highest Revenue ?

The Biotechnology company in Switzerland with the highest Revenue is Roche Holding AG (Swiss Stock Exchange: RO.SW) at USD 68.70 B.
Which Biotechnology company in Switzerland has the lowest Revenue ?

The Biotechnology company in Switzerland with the lowest Revenue is Evolva Holding SA (Swiss Stock Exchange: EVE.SW) at None.

What are the top 10 Biotechnology companies in Switzerland by Revenue ?

The top 10 Biotechnology companies in Switzerland by Revenue are Roche Holding AG, Novartis AG, Sandoz Group AG, Lonza Group AG, Siegfried Holding AG, Tecan Group AG, Bachem Holding AG, medmix AG, PolyPeptide Group AG and Basilea Pharmaceutica AG.
What are the bottom 10 Biotechnology companies in Switzerland by Revenue ?

The bottom 10 Biotechnology companies in Switzerland by Revenue are Evolva Holding SA, MoonLake Immunotherapeutics, NLS Pharmaceutics AG, Oculis Holding AG, Molecular Partners AG, AC Immune SA, CRISPR Therapeutics AG, Santhera Pharmaceuticals Holding AG, ADC Therapeutics SA and Kuros Biosciences AG.